SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions

References

• Angulo P . Nonalcoholic fatty liver disease. N Engl J Med . 2002;346(16):1221–1231. doi:10.1056/NEJMra011775 11961152
   PubMed Web of Science ®Google Scholar
• Michelotti GA , Machado MV , Diehl AM . NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol . 2013;10(11):656–665. doi:10.1038/nrgastro.2013.183 24080776
   PubMed Web of Science ®Google Scholar
• Younossi ZM , Blissett D , Blissett R , et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology . 2016;64(5):1577–1586. doi:10.1002/hep.28785 27543837
   PubMed Web of Science ®Google Scholar
• Rinella ME . Nonalcoholic fatty liver disease: a systematic review. JAMA . 2015;313(22):2263–2273. doi:10.1001/jama.2015.5370 26057287
   PubMed Web of Science ®Google Scholar
• Van der Windt DJ , Sud V , Zhang H , Tsung A , Huang H . The effects of physical exercise on fatty liver disease. Gene Expr . 2018;18(2):89–101.29212576
   PubMedGoogle Scholar
• Vilar-Gomez E , Martinez-Perez Y , Calzadilla-Bertot L , et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology . 2015;149(2):367–378.25865049
   PubMed Web of Science ®Google Scholar
• Rotman Y , Sanyal AJ . Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut . 2017;66(1):180–190.27646933
   PubMed Web of Science ®Google Scholar
• Belfort R , Harrison SA , Brown K , et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med . 2006;355(22):2297–2307.17135584
   PubMed Web of Science ®Google Scholar
• Sato K , Gosho M , Yamamoto T , et al. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Nutrition . 2015;31(7–8):923–930.26059365
   PubMed Web of Science ®Google Scholar
• Abdul-Hai A , Abdallah A , Malnick SDH . Influence of gut bacteria on development and progression of non-alcoholic fatty liver disease. World J Hepatol . 2015;7(12):1679–1684. doi:10.4254/wjh.v7.i12.1679 26140087
   PubMedGoogle Scholar
• Apovian CM , Aronne LJ , Bessesen DH , et al. Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab . 2015;100(2):342–362. doi:10.1210/jc.2014-3415 25590212
   PubMed Web of Science ®Google Scholar
• Zhu C , Kim K , Wang X , et al. Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis. Sci Transl Med . 2018;10(468):pii: eaat0344. doi:10.1126/scitranslmed.aao4496
   Web of Science ®Google Scholar
• Barb D , Portillo-Sanchez P , Cusi K . Pharmacological management of nonalcoholic fatty liver disease. Metabolism . 2016;65(8):1183–1195. doi:10.1016/j.metabol.2016.04.004 27301803
   PubMed Web of Science ®Google Scholar
• Cusi K . Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. Diabetologia . 2016;59(6):1112–1120. doi:10.1007/s00125-016-3952-1 27101131
   PubMed Web of Science ®Google Scholar
• Kuchay MS , Krishan S , Mishra SK , et al. Effect of Empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial). Diabetes Care . 2018;41(8):1801–1808. doi:10.2337/dc18-0165 29895557
   PubMed Web of Science ®Google Scholar
• Inoue M , Hayashi A , Taguchi T , et al. Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease. J Diabetes Investig . Epub 2018 Nov 21.
   Web of Science ®Google Scholar
• Zinman B , Inzucchi SE , Lachin JM , et al. Empagliflozin and cerebrovascular events in patients with type 2 diabetes mellitus at high cardiovascular risk. Stroke . 2017;48(5):1218–1225. doi:10.1161/STROKEAHA.116.015756 28386035
   PubMed Web of Science ®Google Scholar
• Neal B , Perkovic V , Mahaffey KW , et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med . 2017;377(7):644–657. doi:10.1056/NEJMoa1611925 28605608
   PubMed Web of Science ®Google Scholar
• Ismail-Beigi F , Moghissi E , Kosiborod M , Inzucchi SE . Shifting paradigms in the medical management of type 2 diabetes: reflections on recent cardiovascular outcome trials. J Gen Intern Med . 2017;32(9):1044–1051. doi:10.1007/s11606-017-4061-7 28550608
   PubMed Web of Science ®Google Scholar
• Kamei S , Iwamoto M , Kameyama M , et al. Effect of Tofogliflozin on body composition and glycemic control in Japanese subjects with type 2 diabetes mellitus. J Diabetes Res . 2018;2018:6470137. doi:10.1155/2018/6470137 29507863
   PubMed Web of Science ®Google Scholar
• Kumashiro N , Erion DM , Zhang D , et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci USA . 2011;108(39):16381–16385. doi:10.1073/pnas.1113359108 21930939
   PubMed Web of Science ®Google Scholar
• Liu XY , Zhang N , Chen R , Zhao JG , Yu P . Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2 years. J Diabetes Complications . 2015;29(8):1295–1303. doi:10.1016/j.jdiacomp.2015.07.011 26365905
   PubMed Web of Science ®Google Scholar
• Shiba K , Tsuchiya K , Komiya C , et al. Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH. Sci Rep . 2018;8(1):2362. doi:10.1038/s41598-018-19658-7 29402900
   PubMed Web of Science ®Google Scholar
• Tomic D , Kemp WW , Roberts SK . Nonalcoholic fatty liver disease: current concepts, epidemiology and management strategies. Eur J Gastroenterol Hepatol . 2018;30(10):1103–1115. doi:10.1097/MEG.0000000000001235 30113367
   PubMed Web of Science ®Google Scholar
• Brunt EM , Tiniakos DG . Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol . 2010;16(42):5286–5296. doi:10.3748/wjg.v16.i42.5286 21072891
   PubMed Web of Science ®Google Scholar
• Papatheodoridi M , Cholongitas E . Diagnosis of non-alcoholic fatty liver disease (NAFLD): current concepts. Curr Pharm Des . 2018;24(38):4574–4586. doi:10.2174/1381612825666190117102111 30652642
   PubMed Web of Science ®Google Scholar
• Mottin CC , Moretto M , Padoin AV , et al. The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obes Surg . 2004;14(5):635–637. doi:10.1381/096089204323093408 15186630
   PubMed Web of Science ®Google Scholar
• Tobita H , Sato S , Miyake T , et al. Effects of Dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus: a prospective, open-label, uncontrolled study. Curr Ther Res Clin Exp . 2017;87:13–19. doi:10.1016/j.curtheres.2017.07.002 28912902
   PubMed Web of Science ®Google Scholar
• Perumpail BJ , Khan MA , Yoo ER , Cholankeril G , Kim D , Ahmed A . Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol . 2017;23(47):8263–8276. doi:10.3748/wjg.v23.i47.8263 29307986
   PubMed Web of Science ®Google Scholar
• Goldberg D , Ditah IC , Saeian K , et al. Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation. Gastroenterology . 2017;152(5):1090–1099. doi:10.1053/j.gastro.2017.01.003 28088461
   PubMed Web of Science ®Google Scholar
• Baffy G , Brunt EM , Caldwell SH . Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol . 2012;56(6):1384–1391. doi:10.1016/j.jhep.2011.10.027 22326465
   PubMed Web of Science ®Google Scholar
• Larsson SC , Wolk A . Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer . 2007;97(7):1005–1008. doi:10.1038/sj.bjc.6603932 17700568
   PubMed Web of Science ®Google Scholar
• Day CP , James OF . Steatohepatitis: a tale of two “hits”? Gastroenterology . 1998;114(4):842–845.9547102
   PubMed Web of Science ®Google Scholar
• Silverman JF , O’Brien KF , Long S , et al. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol . 1990;85(10):1349–1355.2220728
   PubMed Web of Science ®Google Scholar
• Horst KWT , Serlie MJ . Fructose consumption, lipogenesis, and non-alcoholic fatty liver disease. Nutrients . 2017;9(9):981. doi:10.3390/nu9090981
   PubMed Web of Science ®Google Scholar
• Ferrannini E , Baldi S , Frascerra S , et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes . 2016;65(5):1190–1195. doi:10.2337/db15-1356 26861783
   PubMed Web of Science ®Google Scholar
• Daniele G , Xiong J , Solis-Herrera C , et al. Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes. Diabetes Care . 2016;39(11):2036–2041. doi:10.2337/dc15-2688 27561923
   PubMed Web of Science ®Google Scholar
• Dongiovanni P , Stender S , Pietrelli A , et al. Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. J Intern Med . 2018;283(4):356–370. doi:10.1111/joim.12719 29280273
   PubMed Web of Science ®Google Scholar
• Petta S , Gastaldelli A , Rebelos E , et al. Pathology of non-alcoholic fatty liver disease. Int J Mol Sci . 2016;17(12):2082. doi:10.3390/ijms17122082
   Web of Science ®Google Scholar
• Postic C , Girard J . Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest . 2008;118(3):829–838. doi:10.1172/JCI34275 18317565
   PubMed Web of Science ®Google Scholar
• Perry RJ , Samuel VT , Petersen KF , Shulman GI . The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature . 2014;510(7503):84–91. doi:10.1038/nature13478 24899308
   PubMed Web of Science ®Google Scholar
• Filhoulaud G , Guilmeau S , Dentin R , Girard J , Postic C . Novel insights into ChREBP regulation and function. Trends Endocrinol Metab . 2013;24(5):257–268. doi:10.1016/j.tem.2013.01.003 23597489
   PubMed Web of Science ®Google Scholar
• Wang D , Luo Y , Wang X , et al. The sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents renal and liver disease in western diet induced obesity mice. Int J Mol Sci . 2018;19(1):137. doi:10.3390/ijms19010137
   Web of Science ®Google Scholar
• Junker AE , Gluud L , Holst JJ , Knop FK , Vilsbøll T . Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia. JIM . 2016;279(5):485–493. doi:10.1111/joim.12462
   Web of Science ®Google Scholar
• Sala-Rabanal M , Hirayama BA , Ghezzi C , et al. Revisiting the physiological roles of SGLTs and GLUTs using positron emission tomography in mice. J Physiol . 2016;594(15):4425–4438. doi:10.1113/JP271904 27018980
   PubMed Web of Science ®Google Scholar
• Bonner C , Kerr-Conte J , Gmyr V , et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med . 2015;21(5):512–517. doi:10.1038/nm.3828 25894829
   PubMed Web of Science ®Google Scholar
• Chen J , Williams S , Ho S , et al. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther . 2010;1(2):57–92. doi:10.1007/s13300-010-0006-4 22127746
   PubMedGoogle Scholar
• Katsuno K , Fujimori Y , Takemura Y , et al. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2). J Pharmacol Exp Ther . 2007;320(1):323–330. doi:10.1124/jpet.106.110296 17050778
   PubMed Web of Science ®Google Scholar
• Yokonoa M , Takasua T , Hayashizakia Y , et al. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur J Pharmacol . 2014;15(727):66–74.
   Web of Science ®Google Scholar
• Wiviott SD , Raz I , Bonaca MP , et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med . 2019;380(4):347–357.30415602
   PubMed Web of Science ®Google Scholar
• Lavalle-González FJ , Januszewicz A , Davidson J , et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia . 2013;56(12):2582–2592.24026211
   PubMed Web of Science ®Google Scholar
• Bailey CJ , Gross JL , Pieters A , Bastien A , List JF . Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet . 2010;375(9733):2223–2233.20609968
   PubMed Web of Science ®Google Scholar
• Komiya C , Tsuchiya K , Shiba K , et al. Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction. PLoS One . 2016;11(3):1–19.
   Web of Science ®Google Scholar
• Yokono M , Takasu T , Hayashizaki Y , et al. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur J Pharmacol . 2014;727:66–74.24486393
   PubMed Web of Science ®Google Scholar
• Morgan ES , Tai L-J , Pham NC , et al. Antisense inhibition of glucagon receptor by IONIS-GCGR rx improves type 2 diabetes without increase in hepatic glycogen content in patients with type 2 diabetes on stable metformin therapy. Diabetes Care . 2019;42:4.
   Web of Science ®Google Scholar
• Basu D , Huggins LA , Scerbo D , et al. Mechanism of increased LDL (Low-density lipoprotein) and decreased triglycerides with SGLT2 (Sodium-Glucose Cotransporter 2) inhibition. ATVB . 2018;38(9):2207–2216.
   Web of Science ®Google Scholar
• Leiter LA , Forst T , Polidori D , Balis DA , Xie J , Sha S . Effect of canagliflozin on liver function tests in patients with type 2 diabetes. Diabetes Metab . 2016;42(1):25–32.26575250
   PubMed Web of Science ®Google Scholar
• Sattar N , Fitchetts D , Hantel S , Jyothis T , Zinman G , Zinnman B . Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial. Diabetologia . 2018;61(10):2155–2163.30066148
   PubMed Web of Science ®Google Scholar
• Lee PCH , Gu Y , Yeung MY , et al. Dapagliflozin and empagliflozin ameliorate hepatic dysfunction among chinese subjects with diabetes in part through glycemic improvement: a single-center, retrospective, observational study. Diabetes Ther . 2018;9(1):285–295.29322486
   PubMed Web of Science ®Google Scholar
• Tahara A , Kurosaki E , Yokono M , et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol . 2013;715(1–3):246–255.23707905
   PubMed Web of Science ®Google Scholar
• Tang L , Wu Y , Tian M , et al. Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes. Am J Physiol Endocrinol Metab . 2017;313:563–576.
   PubMed Web of Science ®Google Scholar
• Seko Y , Sumida Y , Tanaka S , et al. Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus. Hepatol Res . 2016;47:1072–1078.27925353
   PubMed Web of Science ®Google Scholar
• Ito D , Shimizu S , Inoue K , et al. Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial. Diabetes Care . 2017;40(10):1364–1372.28751548
   PubMed Web of Science ®Google Scholar
• Itani T , Ishihara T . Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study. Obes Sci Pract . 2018;4(5):477–482.30338118
   PubMed Web of Science ®Google Scholar
• Eriksson JW , Lundkvist P , Jansson PA , et al. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia . 2018;61(9):1923–1934.29971527
   PubMed Web of Science ®Google Scholar
• Ohki T , Isogawa A , Toda N , Tagawa K . Effectiveness of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, as a second-line treatment for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus who do not respond to incretin-based therapies including glucagon-like peptide. Clin Drug Investig . 2016;36(4):313–319.
   PubMed Web of Science ®Google Scholar
• Akuta N , Watanabe C , Kawamura Y , et al. Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: preliminary prospective study based on serial liver biopsies. Hepatol Commun . 2017;1:46–52.29404432
   PubMed Web of Science ®Google Scholar
• Schürks M , Glynn RJ , Rist PM , Tzourio C , Kurth T . Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. BMJ . 2010;341:c5702.21051774
   PubMed Web of Science ®Google Scholar
• Sanyal AJ , Chalasani N , Kowdley KV , et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med . 2010;362:1675–1685.20427778
   PubMed Web of Science ®Google Scholar
• Armstrong MJ , Gaunt P , Aithal GP , et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet . 2016;387:679–690.26608256
   PubMed Web of Science ®Google Scholar
• Aithal GP , Thomas JA , Kaye PV , et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology . 2008;135(4):1176–1184.18718471
   PubMed Web of Science ®Google Scholar
• Bhathena SJ , Berlin E , Judd JT , et al. Effects of ω3 fatty acids and vitamin E on hormones involved in carbohydrate and lipid metabolism in men. Am J Clin Nutr . 1991;54(4):684–688.1832814
   PubMed Web of Science ®Google Scholar
• Klein EA , Thomson IM Jr , Tangen CM , et al. Vitamin E and the risk of prostate cancer: updated results of the selenium and vitamin E cancer prevention trial. JAMA . 2011;306(14):1549–1556.21990298
   PubMed Web of Science ®Google Scholar
• Marso SP , Daniels GH , Brown-Frandsen K , et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med . 2016;375(4):311–322.27295427
   PubMed Web of Science ®Google Scholar
• U.S. National Library of Medicine [homepage on the Internet]. Available from: https://clinicaltrials.gov/. Accessed 6 27, 2019.
   Google Scholar
• Lee DM , Battson ML , Jarrell DK , et al. SGLT2 inhibition via dapagliflozin improves generalized vascular function and alters the gut microbiota in type 2 diabetic mice. Cardiovasc Diabetol . 2018;17:62. 29703207
   PubMed Web of Science ®Google Scholar